Participant flow12

How many started, completed or left each group, period by period.

1 to 12 of 12

Period	Milestone	Group	Participants
Overall Study	STARTED	Placebo	137
Overall Study	STARTED	Rivoglitazone 1.0 mg	274
Overall Study	STARTED	Rivoglitazone 1.5 mg	750
Overall Study	STARTED	Pioglitazone 45 mg	751
Overall Study	COMPLETED	Placebo	96
Overall Study	COMPLETED	Rivoglitazone 1.0 mg	208
Overall Study	COMPLETED	Rivoglitazone 1.5 mg	599
Overall Study	COMPLETED	Pioglitazone 45 mg	579
Overall Study	NOT COMPLETED	Placebo	41
Overall Study	NOT COMPLETED	Rivoglitazone 1.0 mg	66
Overall Study	NOT COMPLETED	Rivoglitazone 1.5 mg	151
Overall Study	NOT COMPLETED	Pioglitazone 45 mg	172

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT00484198/flow